Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Abstract Text:

Weiguo Zhang,Marina Konopleva,Yue-xi Shi,Teresa McQueen,David Harris,Xiaoyang Ling,Zeev Estrov,Alfonso Quintás-Cardama,Donald Small,Jorge Cortes,Michael Andreeff,Weiguo Zhang,Marina Konopleva,Yue-xi Shi,Teresa McQueen,David Harris,Xiaoyang Ling,Zeev Estrov,Alfonso Quintás-Cardama,Donald Small,Jorge Cortes,Michael Andreeff,

BACKGROUND: Internal tandem duplication (ITD) mutations in the juxtamembrane domain-coding sequence of the Fms-like tyrosine kinase 3 (FLT3) gene have been identified in 30% of acute myeloid leukemia (AML) patients and are associated with a poor prognosis. The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concentrations in AML cell lines that harbor FLT3-ITD mutations than in AML cell lines with wild-type FLT3. METHODS: The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model. Effects of sorafenib on apoptosis and signaling in AML cell lines were investigated by flow cytometry and immunoblot analysis, respectively, and the in vivo effects were determined by monitoring the survival of leukemia xenograft-bearing mice treated with sorafenib (groups of 15 mice). In a phase 1 clinical trial, 16 patients with refractory or relapsed AML were treated with sorafenib on different dose schedules. We determined their FLT3 mutation status by a polymerase chain reaction assay and analyzed clinical responses by standard criteria. All statistical tests were two-sided. RESULTS: Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein. In a mouse model, sorafenib decreased the leukemia burden and prolonged survival (median survival in the sorafenib-treated group vs the vehicle-treated group = 36.5 vs 16 days, difference = 20.5 days, 95% confidence interval = 20.3 to 21.3 days; P = .0018). Sorafenib reduced the percentage of leukemia blasts in the peripheral blood and the bone marrow of AML patients with FLT3-ITD (median percentages before and after sorafenib: 81% vs 7.5% [P = .016] and 75.5% vs 34% [P = .05], respectively) but not in patients without this mutation. CONCLUSION: Sorafenib may have therapeutic efficacy in AML patients whose cells harbor FLT3-ITD mutations.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Publishing Authors By Initials

W Zhang,M Konopleva,YX Shi,T McQueen,D Harris,X Ling,Z Estrov,A Quintás-Cardama,D Small,J Cortes,M Andreeff,W Zhang,M Konopleva,YX Shi,T McQueen,D Harris,X Ling,Z Estrov,A Quintás-Cardama,D Small,J Cortes,M Andreeff,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of the National Cancer Institute

VOLUME: 100

Page Numbers: 184-98

Journal Abbreviation: J. Natl. Cancer Inst.

ISSN: 1460-2105

DAY: 29

MONTH: 01

YEAR: 2008

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7503089

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

AFFILIATION: Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Natl Cancer Inst

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia Related Publications

• A diagnostic workstation for neoplastic bone marrow diseases: evaluation on 526 cases.
• Apoptosis effector mechanisms: a requiem performed in different keys.
• Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
• MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
• Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
• Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
• PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
• PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.
• Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
• Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.
• Targeting the leukemia microenvironment.
• The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling.
• The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation.
• Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
• Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
• Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.